Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 333-340

  Keystone, Edward C ^a   Taylor, Peter C ^b   Drescher, Edit ^c   Schlichting, Douglas E ^d   Beattie, Scott D ^d   Berclaz, Pierre Yves ^d   Lee, Chin H ^d   Fidelus Gort, Rosanne K ^e   Luchi, Monica E ^e   Rooney, Terence P ^d   Macias, William L ^d   Genovese, Mark C ^f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c Department of Radiology   (Hungary)

^d ELI LILLY AND COMPANY   (United States)

^e Experimental Station   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARICITINIB; CORTICOSTEROID; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYCHLOROQUINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT; SULFONAMIDE;

ADULT; AGED; ALLERGIC RHINITIS; ANEMIA; ARTICLE; ASTHMA; BACTERIAL PNEUMONIA; BRONCHITIS; CELIAC DISEASE; CHOLECYSTITIS; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; DAS28; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GASTRITIS; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY FAILURE; LACERATION; LEG EDEMA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPHIL COUNT; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; SCLERITIS; SIDE EFFECT; SIMPLIFIED DISEASE ACTIVITY INDEX; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; SULFONAMIDES;

EID: 84921475867     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-206478     Document Type: Article

References (18)

1. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Ann Rev Immunol 1998;16:293-322.
2. O'Shea JJ, Holland SM, Staudt LM. Mechanisms of disease: JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 2013;368:161-70.
3. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72:ii111-15.
4. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298-307.
5. Greenwald MK, Fidelus-Gort R, Levy R, et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract]. Arthritis Rheum 2010;62(Suppl 10):2172.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Smolen JS, Breedveld FC, Eberl G, et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum 1995;38:38-43.
8. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
9. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(Suppl 39):S93-9.
10. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
11. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
12. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(Suppl. 39):S100-8.
13. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
14. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
15. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
16. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
17. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
18. FDA News Release. FDA approves Xeljanz for rheumatoid arthritis. November 6, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm (accessed 21 Nov 2013).